DOES EBV HAVE AN ONCOGENE? NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


DOES EBV HAVE AN ONCOGENE?

UCLA Symp Mol Cell Biol; New Ser 17:273-92 1984. Unique Identifier : AIDSLINE ICDB/86621896
Miller G; Dept. of Epidemiology and Public Health, Yale Univ. Sch. of; Medicine, New Haven, CT 06510

Abstract: Strategies used to identify the genomic regions of Epstein-Barr virus (EBV) involved in viral latency and immortalization are described, and some clinical cases of EBV-associated polyclonal lymphomas are discussed. The primary strategy for analysis of immortalization is to identify the products and eventually, the functions of the transcripts found during latent state. One of the principal products of latency, EBV nucleic acid, has been mapped by gene transfer to the Bam HI K fragment of EBV DNA. The product is an approx 78 K polypeptide which binds to chromosomes at metaphase. A second EBV DNA fragment which induces a second nuclear antigen has also been identified. This fragment, Bam HI M, is not homologous to Bam HI K and is located a considerable distance away on the genome. Sera lacking antibody to Bam HI K nuclear antigen, but recognizing the Bam HI M antigen, detect a nuclear antigen during latency that does not bind metaphase chromosomes. The best evidence that EBV itself encodes an immortalizing function comes from a study of a non-immortalizing mutant, HR-1. The non-transforming HR-1 strain of EBV has defective DNA, which contains rearranged viral DNA and which can disrupt latency. These defective sequences will help to decipher the mechanism of non-permissive infection of lymphocytes by EBV that allows immortalization to occur.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Antigens, Viral/GENETICS Burkitt's Lymphoma Case Report Cell Line Child, Preschool Cloning, Molecular DNA, Viral/GENETICS Female Herpesvirus 4, Human/*GENETICS/*IMMUNOLOGY Human Immunologic Deficiency Syndromes/COMPLICATIONS Infectious Mononucleosis/IMMUNOLOGY Lymphoma/*GENETICS/*IMMUNOLOGY/*MICROBIOLOGY Nucleoproteins/GENETICS/IMMUNOLOGY *Oncogenes MEETING PAPER

KWDacquiredimmunodeficiencysyndrome/complicationsantigens,viral/geneticsburkitt'slymphomacasereportcelllinechild,preschoolcloning,moleculardna,viral/geneticsfemaleherpesvirus4,human/KWDgenetics/KWDimmunologyhumanimmunologicdeficiencysyndromes/complicationsinfectiousmononucleosis/immunologylymphoma/KWDgenetics/KWDimmunology/KWDmicrobiologynucleoproteins/genetics/immunologyKWDoncogenesmeetingpaper
861230
M86C0241

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .